Quarterly report pursuant to Section 13 or 15(d)

CONDENSED BALANCE SHEETS

v3.10.0.1
CONDENSED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 8,427 $ 7,522
Restricted cash 361 361
Receivables 682 65
Inventory 1,293 0
Contract assets 195 0
Prepaid expenses and other current assets 567 362
Total current assets 11,525 8,310
Property and equipment, net 329 595
Total assets 11,854 8,905
Current liabilities:    
Accounts payable 686 821
Accrued clinical trials expenses 453 289
Other accrued liabilities 437 354
Deferred revenue 626 0
Current portion of long-term debt 0 3,000
Total current liabilities 2,202 4,464
Long-term debt, net of discount 4,146 3,584
Derivative liability 17 0
Total liabilities 6,365 8,048
Commitments and contingencies
Stockholders' equity:    
Common stock, $0.001 par value per share; 125,000,000 shares authorized, 39,367,744, and 21,203,744 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively. 39 21
Additional paid-in capital 334,525 324,107
Accumulated deficit (329,075) (323,271)
Total stockholders' equity 5,489 857
Total liabilities and stockholders' equity $ 11,854 $ 8,905